Navigation Links
Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million
Date:1/25/2008

calendar year. As we previously announced, we are currently exploring partnering, licensing, and other strategic alternatives for the endovascular business and we will report back as soon as that review process is completed," Mr. Kaufmann concluded.

Mortgage Draw and Share Repurchase Update. During the quarter the Company took the final $27 million advance under the Company's secured commercial mortgage with Citibank, F.S.B. The mortgage, which is secured by the Company's facility, had provided the Company with the ability to take aggregate advances of up to $35 million through November 25, 2007, all of which have now been taken. Additionally, during the quarter the Company repurchased 323,000 shares of its common stock for a total of $8.8 million under the previously announced $25 million share repurchase program.

Fiscal 2008 Third Quarter Forecast. For the third quarter of fiscal year 2008, the Company believes that its net sales will be in the range of $13.7 to $14.2 million and royalties will be in the range of $6.6 to $6.8 million. Total revenues are expected to be in the range of $20.3 to $21.0 million. Diluted earnings per share are expected to be $0.25 to $0.27.

Conference Call and Webcast. The Company will host a conference call on Friday, January 25, 2008 at 9:00 a.m. Eastern Time. To participate in the conference call, interested parties should dial 1-612-332-0637. In addition, a live webcast of the call can be accessed by visiting the Investor Relations page under the Conferences & Webcasts link of the Kensey Nash website at http://www.kenseynash.com and clicking on Webcast. The teleconference call will also be available for replay starting Friday, January 25, 2008 at 11:00 a.m. Eastern Time through Friday, February 8, 2008 at 11:59 p.m. Eastern Time by dialing 1-800-475-6701 with an access code of 905138.

About Kensey Nash Corporation. Kensey Nash Corporation is a leading
'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Kensey Nash Corporation Announces Its Second Quarter 2008 Earnings Release Date and Teleconference
2. Kensey Nash to Present at the 19th Annual Piper Jaffray Health Care Conference
3. Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform
4. Kensey Nash Reports First Quarter Fiscal Year 2008 Results
5. Kensey Nash Reports Acceleration of Stock Awards Triggered by Shareholder Acquisition of Greater Than 20% of Outstanding Shares
6. Kensey Nash Announces $25 Million Stock Repurchase Program
7. Kensey Nash Corporation Announces its First Quarter 2008 Earnings Release Date and Teleconference
8. WellPoint Reports Fourth Quarter and Full Year 2007 Results
9. Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance
10. TeamStaff Reports Fourth Quarter and Fiscal 2007 Results; Posts Fourth Quarter Income From Operations
11. Health care reform and 2008 elections: New reports examine candidates plans, publics views
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...PRNewswire-USNewswire/ -- The Generic,Pharmaceuti...ement today from,GPhA President and CEO Kathleen ...C) roundtable on "Emerging Health Care Competition...t the FTC is conducting this roundtable demonstrat...umers have access to safe and,affordable biogener...
(Date:11/21/2008)...1 New research at West...less, spitless tobacco product aimed at young adul...that RJ Reynolds, Camel Snus - touted as a sociall...urprisingly high levels of nicotine. , , "C...nuff products," said Bruce Adkins of the state Div...
(Date:11/21/2008).... 21 Today, prescription...on in treating 88 percent of patients suffering ch...ated for a chronic condition account for 96 percen... of all medical costs. A proprietary new pharmacy...Solutions, Inc. (NYSE: MHS ) significantly reduc...
(Date:11/21/2008)...re/ -- In a statewide survey, 33 physicians creden...ery at Presbyterian Hospital of Dallas were honore... " Super Doctors ." , , Each year, the publ...al Media, Inc. to survey more than 38,000 medical ...f you needed medical care, which doctor would you ...
Breaking Medicine News(10 mins):Health News:GPhA Statement on FTC Roundtable on Biogenerics 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2
... pregnancies and abortions to stem selective abort...to a report. India has only 927 females for every...ge of 1,050 females -- mainly due to selective abo...ere many people prefer to have male children. "Th...
...ng attack on Hollywood star Eddie Murphy and has c...r colleague Mel B in a callous way after she got p... actor in a new TV show that will be sired soon. ...finitely. I'd chop his dick off too, the News of t...
...see steamy shots of co-star Daniel Radcliffe in an... realised how handsome Radcliffe is, after looking.... (It's) the first time I've really thought, 'Ooh,...good looking, Contactmusic quoted her, as saying. ...
...the brain that are involved with suppressing unple...ions for treating depression or post traumatic st...day. The concept of memory suppression has been a...ts for a century, but in this study neuroscientist...
Other Medicine News:Health News:India to Monitor Pregnancies to Check Girl Foeticide: Report 2Health News:Research into Suppressed Memories Could Help Treatment for Depression 2
(Date:11/19/2008)...SAND OAKS, Calif., Nov. 19 /PRNewswire-FirstCall/ ...keda Oncology Company, a subsidiary of,Takeda Pha...ounced that,enrollment in the Phase 3 MONET1 tria...ith paclitaxel and carboplatin for the first-line ...(NSCLC) has been temporarily suspended,following ...
(Date:11/19/2008)...Jude scientists report basic findings on critical ...how to better treat an array of disorders , ,... -- Scientists at St. Jude Children,s Research Ho... one of the body,s enzyme workhorses called calpai...ers, calpains function in many cellular processes,...
(Date:11/19/2008)...RK, Del., Nov. 19 Isogen, a contra... sterile filling, today announced the first,phase...en was founded to,specifically address the proces...ated with the $2 billion highly-niched, low-volume...ing market segment. , Companies can invest ...
(Date:11/18/2008)...ON, November 19 NeuroDis...ervice provider and drug development Company,and...ex: 4565), a leading,international biopharmaceuti...s presenting further pivotal pre-clinical efficacy...g is a potential therapy for neuropathic pain and ...
Breaking Medicine Technology:Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3Isogen Launches Major New Facility to Address Global Biopharma Demand 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3Select Comfort Helps Families Sleep Better in Los Angeles 13410 1Select Comfort Helps Families Sleep Better in Los Angeles 13410 2Select Comfort Helps Families Sleep Better in Los Angeles 13410 3Cochlear implant recipients experience improvement in quality of life 13407 1A combination therapy of 3 vasodilators may treat portopulmonary hypertension 13404 1A combination therapy of 3 vasodilators may treat portopulmonary hypertension 13404 2Health Secretarys Statewide Tour to Discuss Health Insurance for All Pennsylvanians Makes Stop in Cambria County 13401 1Health Secretarys Statewide Tour to Discuss Health Insurance for All Pennsylvanians Makes Stop in Cambria County 13401 2
...NNA, Austria, June 11, 2007 /PRNewswire/ -- GlaxoS...nal, pivotal Phase III,study of its investigationa...A(R) (eltrombopag olamine). Data from this study,s... in a,statistically significant increase in platel...nts with chronic idiopathic,thrombocytopenic purpu...
...sults Presented at the 12th Congress of European H...ne 11, 2007 /PRNewswire-FirstCall/ --,Immunomedics...veloping monoclonal antibodies to treat cancer and... presented at the 12th Congress,of EHA in Vienna, ...h non-Hodgkin,s lymphoma (NHL) treated with a new,...
Other Medicine Technology:Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 2Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 3Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 4Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 5Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 6Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5
The safePICO is a prebarcoded arterial sampler that helps you ensure patient and caregiver safety. SafePICO is part of 1st automatic, the worlds first automatic blood gas analysis system.
Rapid exchange thrombectomy never handled like this before. ,Designed with tortuous anatomy in mind, the Spiroflex catheters unique spiral cut shaft, soft tip and hydrophilic coating provide out
...adiometer University is the only online source of ...atory therapists, critical care nurses and other h...ced courses are available online 24/7, so you can ...ly available, and a certificate is issued upon cou...
The FLEXLINK software links sampler, patient and operator IDs at the bedside, making data readily available to caregivers and eliminating the risk of incorrect patient identification. , ,FLEXLIN
Medicine Products: